Phenomix Corporation

Synthorx Inc. ,a biotechnology company using synthetic biology to discover and develop novel protein therapeutics, has named Dr. Laura Shawver president, director and CEO. Prior to joining Syntho

Type 2 diabetes isn’t an obvious spot for any aspiring biotech entrepreneur to invest hard-raised dollars. The highly competitive marketplace is dominated by Sanofi , desperate as $7 billion Lantu

EnVivo Pharmaceuticals, a company dedicated to developing novel CNS therapies, has appointed Christopher Burnley chief business officer. Mr Burnley was previously a founder and CEO of VetRx, a biotech

[Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog .] Perhaps you’ll feast on corned beef, ca